Takeyuki Kono1, Koji Sakamoto2, Seiichi Shinden2, Kaoru Ogawa3. 1. Department of Otolaryngology and Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo, 160-8582, Japan; Division of Otolaryngology and Head and Neck Surgery, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya-Shi, Tochigi, 321-0974, Japan. Electronic address: take.k1227@gmail.com. 2. Division of Otolaryngology and Head and Neck Surgery, Saiseikai Utsunomiya Hospital, 911-1 Takebayashi, Utsunomiya-Shi, Tochigi, 321-0974, Japan. 3. Department of Otolaryngology and Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjyuku-ku, Tokyo, 160-8582, Japan.
Abstract
BACKGROUND & AIMS: Malnutrition is common in patients with head and neck cancer (HNSCC). It may be related to severe adverse toxicity as a result of radiotherapy. The aim was to investigate nutritional screening factors for severe adverse events. METHODS: A retrospective chart review of 101 patients who underwent radiotherapy from 2009 to 2013 was performed. The relationships among severe adverse events and pretreatment nutritional parameters, including static variables (serum albumin, total protein, total lymphocyte counts, body mass index), dynamic variables (retinol-binding protein, transferrin, pre-albumin), and nutritional screening tools (Onodera's Prognostic Nutrition Index [O-PNI]; Nutrition Risk Index; Controlling Nutritional Status [CONUT] score; Nutritional Risk Screening 2002) were evaluated in addition to patient and treatment factors. RESULTS: According to the static parameters, approximately 30% of patients were malnourished before treatment. Twenty-four patients exhibited severe adverse events. On univariate analysis, combined chemotherapy, advanced staging, O-PNI <40, and CONUT score ≥5 were significant predictors of severe adverse events. Multivariate analysis revealed that O-PNI <40 and combined chemotherapy independently predict severe adverse events. CONCLUSIONS: O-PNI is considered a useful nutritional factor for predicting severe adverse events in HNSCC patients undergoing chemoradiotherapy and facilitates the planning of aggressive nutritional interventions prior to treatment.
BACKGROUND & AIMS: Malnutrition is common in patients with head and neck cancer (HNSCC). It may be related to severe adverse toxicity as a result of radiotherapy. The aim was to investigate nutritional screening factors for severe adverse events. METHODS: A retrospective chart review of 101 patients who underwent radiotherapy from 2009 to 2013 was performed. The relationships among severe adverse events and pretreatment nutritional parameters, including static variables (serum albumin, total protein, total lymphocyte counts, body mass index), dynamic variables (retinol-binding protein, transferrin, pre-albumin), and nutritional screening tools (Onodera's Prognostic Nutrition Index [O-PNI]; Nutrition Risk Index; Controlling Nutritional Status [CONUT] score; Nutritional Risk Screening 2002) were evaluated in addition to patient and treatment factors. RESULTS: According to the static parameters, approximately 30% of patients were malnourished before treatment. Twenty-four patients exhibited severe adverse events. On univariate analysis, combined chemotherapy, advanced staging, O-PNI <40, and CONUT score ≥5 were significant predictors of severe adverse events. Multivariate analysis revealed that O-PNI <40 and combined chemotherapy independently predict severe adverse events. CONCLUSIONS: O-PNI is considered a useful nutritional factor for predicting severe adverse events in HNSCCpatients undergoing chemoradiotherapy and facilitates the planning of aggressive nutritional interventions prior to treatment.
Authors: Gema Bruixola; Javier Caballero; Federica Papaccio; Angelica Petrillo; Aina Iranzo; Miguel Civera; Miriam Moriana; Neus Bosch; Maria Maroñas; Ines González; Miguel Pastor; Andrés Cervantes Journal: ESMO Open Date: 2018-10-24
Authors: Anna C H Willemsen; Ann Hoeben; Roy I Lalisang; Ardy Van Helvoort; Frederik W R Wesseling; Frank Hoebers; Laura W J Baijens; Annemie M W J Schols Journal: J Cachexia Sarcopenia Muscle Date: 2019-09-19 Impact factor: 12.910